Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107, for… EP News Bureau Jan 9, 2025 The study's primary objective is to assess the safety and tolerability of SUVN-I6107, a true muscarinic M1 positive allosteric…
